Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.
Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators. Pope MK, et al. Among authors: cappato r. BMJ. 2021 Oct 27;375:e066450. doi: 10.1136/bmj-2021-066450. BMJ. 2021. PMID: 34706884 Free PMC article.
Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta-blocker STrategy plus ICD trial.
Raviele A, Bongiorni MG, Brignole M, Cappato R, Capucci A, Gaita F, Gulizia M, Mangiameli S, Montenero AS, Pedretti RF, Uriarte JA, Sermasi S, Nisam S; BEST + ICD Trial Investigators. Raviele A, et al. Among authors: cappato r. Europace. 2005 Jul;7(4):327-37. doi: 10.1016/j.eupc.2005.03.003. Europace. 2005. PMID: 16028343 Clinical Trial.
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD, Cappato R, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca MI, Vardas PE, Kirchhof P, Hohnloser SH, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M. Ezekowitz MD, et al. Among authors: cappato r. Am Heart J. 2014 May;167(5):646-52. doi: 10.1016/j.ahj.2013.12.024. Epub 2014 Jan 14. Am Heart J. 2014. PMID: 24766973 Clinical Trial.
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Cappato R, et al. Eur Heart J. 2014 Dec 14;35(47):3346-55. doi: 10.1093/eurheartj/ehu367. Epub 2014 Sep 2. Eur Heart J. 2014. PMID: 25182247 Clinical Trial.
Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry providing baseline data (CLOT-AF).
Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, Morandi E, van Eickels M, Cohen A. Lip GY, et al. Among authors: cappato r. Am Heart J. 2015 Apr;169(4):464-71.e2. doi: 10.1016/j.ahj.2014.12.020. Epub 2015 Jan 6. Am Heart J. 2015. PMID: 25819852 Free article. Clinical Trial.
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Hohnloser SH, Cappato R, Ezekowitz MD, Evers T, Sahin K, Kirchhof P, Meng IL, van Eickels M, Camm AJ; X-VeRT Steering Committee and Investigators. Hohnloser SH, et al. Among authors: cappato r. Europace. 2016 Feb;18(2):184-90. doi: 10.1093/europace/euv294. Epub 2015 Oct 20. Europace. 2016. PMID: 26487668 Free PMC article. Clinical Trial.
Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).
Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, van Eickels M, Cohen A; X-TRA study and CLOT-AF registry investigators. Lip GY, et al. Among authors: cappato r. Am Heart J. 2016 Aug;178:126-34. doi: 10.1016/j.ahj.2016.05.007. Epub 2016 May 17. Am Heart J. 2016. PMID: 27502860 Free article.
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbuchel H, Lanz HJ, Mont L, Morillo CA, Smolnik R, Yin OQP, Kautzner J. Hohnloser SH, et al. Among authors: cappato r. Clin Cardiol. 2018 Apr;41(4):440-449. doi: 10.1002/clc.22918. Epub 2018 Apr 17. Clin Cardiol. 2018. PMID: 29663464 Free PMC article. Clinical Trial.
[Appropriateness criteria for the management of anticoagulant therapy in complex patients with atrial fibrillation. The opinion of a group of expert Italian cardiologists].
Botto GL, Padeletti L, Ammirati F, Calò L, Calvi V, Cappato R, Capucci A, D'Onofrio A, Grimaldi M, Lombardi F, Lunati M, Senatore G, Themistoclackis S, Boriani G. Botto GL, et al. Among authors: cappato r. G Ital Cardiol (Rome). 2018 Oct;19(10):591-600. doi: 10.1714/2978.29844. G Ital Cardiol (Rome). 2018. PMID: 30281046 Italian.
295 results